CalciMedica (CALC) Competitors $1.62 +0.04 (+2.53%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CALC vs. ORMP, SAVA, JMAC, CLLS, IVVD, ADAG, ENTX, ZNTL, OKYO, and JSPRShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Oramed Pharmaceuticals (ORMP), Cassava Sciences (SAVA), Maxpro Capital Acquisition (JMAC), Cellectis (CLLS), Invivyd (IVVD), Adagene (ADAG), Entera Bio (ENTX), Zentalis Pharmaceuticals (ZNTL), OKYO Pharma (OKYO), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Its Competitors Oramed Pharmaceuticals Cassava Sciences Maxpro Capital Acquisition Cellectis Invivyd Adagene Entera Bio Zentalis Pharmaceuticals OKYO Pharma Jasper Therapeutics CalciMedica (NASDAQ:CALC) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability. Does the media refer more to CALC or ORMP? In the previous week, CalciMedica had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 5 mentions for CalciMedica and 4 mentions for Oramed Pharmaceuticals. CalciMedica's average media sentiment score of 0.65 beat Oramed Pharmaceuticals' score of 0.39 indicating that CalciMedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CALC or ORMP? CalciMedica currently has a consensus target price of $18.00, indicating a potential upside of 1,011.11%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, CALC or ORMP? CalciMedica has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Which has stronger earnings and valuation, CALC or ORMP? CalciMedica has higher earnings, but lower revenue than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$13.70M-$1.56-1.04Oramed Pharmaceuticals$1.34M66.76-$19.06M-$0.44-4.98 Do institutionals and insiders believe in CALC or ORMP? 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is CALC or ORMP more profitable? Oramed Pharmaceuticals' return on equity of -11.34% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -171.81% -100.43% Oramed Pharmaceuticals N/A -11.34%-10.73% SummaryCalciMedica beats Oramed Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.62M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.0421.2326.5720.02Price / SalesN/A280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book1.517.498.065.50Net Income-$13.70M-$55.05M$3.15B$248.50M7 Day Performance13.29%2.58%1.72%2.61%1 Month Performance-0.61%5.22%3.92%5.42%1 Year Performance-61.97%5.04%35.02%20.76% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica3.2492 of 5 stars$1.62+2.5%$18.00+1,011.1%-60.6%$22.62MN/A-1.0430ORMPOramed Pharmaceuticals0.5732 of 5 stars$2.19-2.9%N/A-16.1%$89.26M$2M-4.9710News CoverageGap DownSAVACassava Sciences4.2116 of 5 stars$1.84+1.4%$54.50+2,870.0%-83.0%$88.17MN/A-1.2230News CoverageJMACMaxpro Capital AcquisitionN/A$6.56+0.7%N/A+2,947.6%$88.06MN/A0.002,021Gap DownCLLSCellectis3.0493 of 5 stars$1.55+1.3%$4.00+158.9%-12.2%$87.82M$49.22M-1.84290News CoverageIVVDInvivyd3.2767 of 5 stars$0.74+3.4%$5.85+691.6%-34.3%$87.69M$25.38M-0.61100News CoverageGap UpADAGAdagene1.9963 of 5 stars$1.86-4.6%$8.00+330.1%-35.1%$87.63M$100K0.00260Gap UpHigh Trading VolumeENTXEntera Bio2.8359 of 5 stars$1.91+0.5%$10.00+423.6%+11.7%$86.81M$180K-7.3520Positive NewsGap UpZNTLZentalis Pharmaceuticals1.9516 of 5 stars$1.20+3.0%$8.37+600.1%-65.3%$85.98M$67.43M-0.38160OKYOOKYO Pharma2.6581 of 5 stars$2.53-1.6%$7.00+176.7%+142.5%$85.62MN/A0.007Gap UpJSPRJasper Therapeutics2.0938 of 5 stars$5.72+3.1%$59.25+935.8%-70.1%$85.61MN/A-1.0920 Related Companies and Tools Related Companies Oramed Pharmaceuticals Alternatives Cassava Sciences Alternatives Maxpro Capital Acquisition Alternatives Cellectis Alternatives Invivyd Alternatives Adagene Alternatives Entera Bio Alternatives Zentalis Pharmaceuticals Alternatives OKYO Pharma Alternatives Jasper Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALC Stock Alerts